Extended 10-Panel
Broad 10-substance screening covering CDT, cocaine, ketamine, amphetamines, 3-MMC, LSD, GHB, phenibut, heroin marker, and opiates.
Every result includes a professional assessment from a BIG-registered doctor. For treatment decisions, discuss your results with your GP.
The Zuiver phenibut urine screening provides targeted, qualitative detection of phenibut and its metabolites. This specialised test addresses a gap in standard panels, offering reliable results for extended workplace and clinical screening.
This test detects the presence of phenibut and its metabolites in urine. Phenibut is a GABA-B receptor agonist originally developed in Russia. The test provides a qualitative result indicating whether phenibut metabolites are present above the assay cut-off level.
Phenibut use may be associated with dependence, withdrawal symptoms, and adverse effects on the central nervous system. Because phenibut is often not included in standard drug panels, targeted testing can be important for accurate clinical assessment. Consult a healthcare professional for interpretation of results.
Testing may be relevant when phenibut use is suspected, during substance abuse treatment monitoring, or as part of an extended drug screening panel. Phenibut is increasingly encountered in clinical and forensic settings. Consult a healthcare professional for guidance.
Support your well-being through regular physical activity, adequate sleep, and stress management techniques. If you have concerns about supplement or substance use, consult a qualified healthcare professional. Avoid purchasing unregulated substances online.
This marker is included in the following test panels.
Broad 10-substance screening covering CDT, cocaine, ketamine, amphetamines, 3-MMC, LSD, GHB, phenibut, heroin marker, and opiates.